1.Corrigendum: Comparative analysis of cancer statistics in China and the United States in 2024.
Yujie WU ; Siyi HE ; Mengdi CAO ; Yi TENG ; Qianru LI ; Nuopei TAN ; Jiachen WANG ; Tingting ZUO ; Tianyi LI ; Yuanjie ZHENG ; Changfa XIA ; Wanqing CHEN
Chinese Medical Journal 2025;138(10):1260-1260
2.Analysis of the Disease Burden of Gastric Cancer in Chi-na,Japan and Republic of Korea from 1990 to 2021 and Prediction of Trends from 2022 to 2031
Yujie WU ; Siyi HE ; Mengdi CAO ; Yi TENG ; Qianru LI ; Jiachen WANG ; Nuopei TAN ; Tingting ZUO ; Changfa XIA ; Jufang SHI ; Wanqing CHEN
China Cancer 2025;34(8):626-635
[Purpose]To analyze the epidemiology and disease burden of gastric cancer in China,Japan and Republic of Korea from 1990 to 2021 and to predict changing trends from 2022 to 2031.[Methods]Data were obtained from the Global Burden of Disease(GBD)database.Age-stan-dardized incidence rate(ASIR),age-standardized mortality rate(ASMR),crude incidence rate(CIR),crude mortality rate(CMR),and disability-adjusted life years(DALY)rate for China,Japan and Republic of Korea from 1990 to 2021 were analyzed.Joinpoint regression software was used to analyze trends and calculate annual percentage changes.The autoregressive integrated moving average(ARIMA)model was applied to predict incidence and mortality from 2022 to 2031.[Results]In 2021,China had 611 799 new gastric cancer cases and 445 013 deaths,with an ASIR of 29.05/105 and an ASMR of 21.51/105,both significantly higher than those in Japan and Republic of Korea.Among men in China,both the ASIR(44.48/105)and ASMR(32.61/105)were the highest among the three countries,exceeding those in Japan(38.77/105,20.26/105)and Re-public of Korea(38.98/105,20.50/105).Among women,China had the highest number of new cases,but its ASIR(15.23/105)was slightly lower than Republic of Korea's(15.57/105)and higher than Japan's(14.66/105).However,China's ASMR among women(12.02/105)remained significantly higher than Japan's(7.64/105)and Republic of Korea's(8.08/105).From 1990 to 2021,ASIR,ASMR and DALY rates for gastric cancer declined in all three countries,but the reduction in China was significantly smaller than that in Japan and Republic of Korea,with Republic of Korea showing the steepest declines across all indicators.ARIMA model predictions indicated significant differences in disease burden among the three countries from 2022 to 2031.ASIR is projected to continue declining in China and Republic of Korea,reaching 22.87/105 and 12.45/105,respectively by 2031,while in Japan it is predicted to rise to 26.55/105.ASMR is projected to decline in all three countries,reaching 13.71/105(China),10.44/105(Japan),and 9.08/105(Republic of Korea)in 2031.[Conclusion]Among China,Japan and Republic of Korea,China had the highest ASIR and ASMR of gastric cancer in 2021.Moreover,from 1990 to 2021,the reductions in ASIR,ASMR and DALY rates for gastric cancer were the smallest in China compared to Japan and Republic of Korea.These findings suggest that the disease burden of gastric cancer remains substantial in China,high-lighting the need for increased efforts in gastric cancer screening and early diagnosis and treatment.
3.Trends and Decompostion of Disease Burden for Lung Cancer Worldwide and in China from 1990 to 2021
Tianyi LI ; Yuanjie ZHENG ; Yi TENG ; Qianru LI ; Tingting ZUO ; Nuopei TAN ; Jiachen WANG ; Siyi HE ; Mengdi CAO ; Changfa XIA ; Wanqing CHEN
China Cancer 2025;34(5):355-367
[Purpose]To analyze the trends of disease burden for lung cancer worldwide and in China from 1990 to 2021.[Methods]Data of the disease burden of lung cancer and population demographics in 1990 and 2021 stratified by sex and age groups for global,five SDI quintiles re-gions,and eight countries including China,Japan,Republic of Korea,United Kingdom,France,United States,Canada,and Australia were extracted from the Global Burden of Disease Study 2021(GBD 2021)database.The age-standardized mortality rate(ASMR)and age-standard-ized disability-adjusted life year rate(ASDR)of lung cancer attributable to 7 level-3 risk factors in China for 1990 and 2021 were also extracted.Counterfactual analysis was used to decompose changes in lung cancer deaths and DALY from 1990 to 2021 into four contributing factors:popu-lation size,population structure,age-standardized incidence or prevalence,and lung cancer case fatality or disease severity.The percentage changes in lung cancer deaths and DALY attributed to these four factors were calculated respectively.[Results]In 2021,there were 934 704 new cases and 814 364 deaths of lung cancer in China.From 1990 to 2021,the incidence,preva-lence,mortality,and DALY rates of lung cancer in China increased faster than those worldwide and in high-middle SDI regions,which was similar to Japan and Republic of Korea.In contrast,the mortality rates of lung cancer decreased in United States and United Kingdom;and the DALY rates of lung cancer decreased in United States,United Kingdom,Canada and Australia.From 1990 to 2021,the age-related lung cancer deaths and DALY in China increased by 193.91%and 146.20%,respectively.The primary contributor to the increase in lung cancer deaths was population aging(102.82%)among men and rising age-standardized incidence(119.00%)among women,while the primary contributor to the increase in DALY was rising age-standardized prevalence for both men(153.12%)and women(218.77%).In 2021,the top three risk factors contributing to lung cancer ASMR and ASDR in China were smoking,particulate matter pollution and occupational carcinogen exposure.Compared with 1990,the ASMR of lung cancer and its proportion at-tributable to particulate matter pollution and low dietary fruits were decreased,while the propor-tions in ASDR of lung cancer attributable to smoking and secondhand smoke increased.[Conclu-sion]Lung cancer is a major public health challenge in China.Compared with worldwide,high-middle SDI regions and certain developed countries,China has experienced faster growth in the incidence,prevalence,mortality and DALY of lung cancer,especially among women.To reduce disease burden,sustained efforts on lung cancer prevention and control are urgently required in China.
4.Non-drug intervention for nipple pain or injury in breastfeeding women:a summary of best evidence
Mengdi CAO ; Yanyan WANG ; Liangyi YAO ; Xin CHEN ; Jing LI ; Xing LI
Modern Clinical Nursing 2025;24(5):65-72
Objective To search,evaluate and summarise the best evidence on non-drug intervention for nipple pain or injury in breastfeeding mothers.Methods Based on the"6S pyramid"evidence model,desktop searches were conducted on databases of UpToDate,Joanna Briggs Institute evidence-based practice database(JBI),National Guideline Clearinghouse(NGC),National Institute for health and Care Excellence(NICE),Guidelines International Network(GIN),Registered Nurses'Association of Ontario(RNAO),American College of Obstetricians and Gynecologists(ACOG),Medlive,Chinese Medical Association(CMA)website,Breastfeeding Medical Association(BMA),CNKI,Wanfang Data,SinoMed,Cochrance Library,PubMed,Embase,Web of Science,and CINAHL for literature in non-drug interventions for nipple pain or injury in breastfeeding women.The literature included clinical guidelines,decisions,recommended practices,evidence summaries,expert consensus,systematic reviews and randomized controlled trials(RCTs).The searched databases spanned from 1st January,2013 to 30th April,2024.Two researchers who were trained in evidence-based nursing independently evaluated the methodological quality,extracted and integrated evidence from eligible literature.Results A total of 15 documents were included,consisting of 5 clinical guidelines,2 clinical decisions,1 expert consensus,6 systematic evaluations and 1 RCT.Thirty-one pieces of evidence were summarised across 4 categories:accurate perinatal assessment,feeding guidance,non-drug intervention and health education.Conclusion The summarised best evidence on non-drug intervention for nipple pain or injury in breastfeeding women provides an evidence-based basis for clinical healthcare professionals.
5.A scoping review on the current status and influencing factors of adherence to lymphedema prevention behaviors in postoperative breast cancer patients
Mengdi CAO ; Yanyan WANG ; Jing LI ; Xing LI ; Zezhao WANG
Chinese Journal of Modern Nursing 2025;31(34):4743-4749
Objective:To conduct a scoping review on the current status and influencing factors of adherence to lymphedema prevention behaviors among postoperative breast cancer patients, with the aim of providing a scientific basis for developing targeted interventions.Methods:A comprehensive search was conducted in both Chinese and English databases, including China National Knowledge Infrastructure, Wanfang Data, SinoMed, PubMed, Cochrane Library, Embase, CINAHL, and Web of Science, for literature published up to August 31, 2024, related to adherence to lymphedema prevention behaviors in breast cancer survivors. Eligible articles were screened, and data were extracted to analyze adherence levels. Influencing factors were mapped to the domains of the Theoretical Domains Framework to identify and analyze key behavioral determinants.Results:A total of 15 articles were included: nine quantitative and six qualitative. Overall, adherence to lymphedema prevention behaviors among postoperative breast cancer patients was found to be suboptimal. A total of 25 influencing factors were identified and categorized into eight theoretical domains: knowledge (lymphedema awareness) ; skills (coping strategies, time since surgery) ; beliefs about capabilities (self-efficacy, illness perception, unawareness of tumor stage, surgical type, symptom distress) ; beliefs about consequences (outcome expectations, attitudes) ; emotions (negative emotions, fatigue, age) ; behavior regulation (self-regulation, exercise habits, behavioral control) ; social influences (social support, family support, marital status, behavioral cues) ; environmental context and resources (healthcare access, ethnicity, professional supervision, financial status, employment situation) .Conclusions:Adherence to lymphedema prevention behaviors in postoperative breast cancer patients remains unsatisfactory, with influencing factors being multifaceted, diverse, and overlapping. Future efforts should focus on uncovering the potential interrelationships among these factors to enhance adherence and support long-term self-management in this population.
6.A scoping review on the current status and influencing factors of adherence to lymphedema prevention behaviors in postoperative breast cancer patients
Mengdi CAO ; Yanyan WANG ; Jing LI ; Xing LI ; Zezhao WANG
Chinese Journal of Modern Nursing 2025;31(34):4743-4749
Objective:To conduct a scoping review on the current status and influencing factors of adherence to lymphedema prevention behaviors among postoperative breast cancer patients, with the aim of providing a scientific basis for developing targeted interventions.Methods:A comprehensive search was conducted in both Chinese and English databases, including China National Knowledge Infrastructure, Wanfang Data, SinoMed, PubMed, Cochrane Library, Embase, CINAHL, and Web of Science, for literature published up to August 31, 2024, related to adherence to lymphedema prevention behaviors in breast cancer survivors. Eligible articles were screened, and data were extracted to analyze adherence levels. Influencing factors were mapped to the domains of the Theoretical Domains Framework to identify and analyze key behavioral determinants.Results:A total of 15 articles were included: nine quantitative and six qualitative. Overall, adherence to lymphedema prevention behaviors among postoperative breast cancer patients was found to be suboptimal. A total of 25 influencing factors were identified and categorized into eight theoretical domains: knowledge (lymphedema awareness) ; skills (coping strategies, time since surgery) ; beliefs about capabilities (self-efficacy, illness perception, unawareness of tumor stage, surgical type, symptom distress) ; beliefs about consequences (outcome expectations, attitudes) ; emotions (negative emotions, fatigue, age) ; behavior regulation (self-regulation, exercise habits, behavioral control) ; social influences (social support, family support, marital status, behavioral cues) ; environmental context and resources (healthcare access, ethnicity, professional supervision, financial status, employment situation) .Conclusions:Adherence to lymphedema prevention behaviors in postoperative breast cancer patients remains unsatisfactory, with influencing factors being multifaceted, diverse, and overlapping. Future efforts should focus on uncovering the potential interrelationships among these factors to enhance adherence and support long-term self-management in this population.
7.Analysis of the change trend in the burden of 5 common malignant tumors of digestive system in the Chinese population from 1990 to 2021
Jiachen WANG ; Siyi HE ; Mengdi CAO ; Yi TENG ; Qianru LI ; Nuopei TAN ; Yujie WU ; Tingting ZUO ; Tianyi LI ; Yuanjie ZHENG ; Wanqing CHEN
Chinese Journal of Digestive Surgery 2025;24(2):213-222
Objective:To investigate the change trend in the burden of 5 common malignant tumors of digestive system (esophageal cancer, gastric cancer, colorectal cancer, pancreatic cancer and liver cancer) in the Chinese population from 1990 to 2021.Methods:The descriptive epidemio-logic method was conducted. The number of new cases, crude incidence rate, age-standardized incidence rate, the number of deaths, crude mortality rate and age-standardized mortality rate of 5 common malignant tumors of digestive system in the Chinese population from 1990 to 2021 of the Global Burden of Disease were collected. The age-standardized rate was calculated based on the standardized demographics of the whole world in the Global Burden of Disease for the year 2021. Observation indicators: (1) The incidence of 5 common malignant tumors of digestive system in the Chinese population from 1990 to 2021; (2) the mortality of 5 common malignant tumors of digestive system in the Chinese population from 1990 to 2021; (3) the change trend of age-standardized incidence rate of 5 common malignant tumors of digestive system in the Chinese population from 1990 to 2021; (4) the change trend of age-standardized mortality rate of 5 common malignant tumors of digestive system in the Chinese population from 1990 to 2021. The Joinpoint regression model was constructed for trend analysis, specifically to calculate the annual percentage change, average annual percentage change (AAPC), and their 95% confidence interval ( CI) for age-standardized incidence and mortality rates for each cancer type at different time periods. Results:(1) The incidence of 5 common malignant tumors of digestive system in the Chinese population from 1990 to 2021. The number of new cases of esophageal cancer, gastric cancer, colorectal cancer, pancreatic cancer and liver cancer in the Chinese population changed from 207 495, 407 471, 158 389, 37 818 and 96 434 in 1990 to 320 805, 611 799, 658 321, 118 665 and 196 637 in 2021. The crude incidence rates of the above cancer types changed from 17.64/100 000, 34.64/100 000, 13.46/100 000, 3.21/100 000, 8.20/100 000 in 1990 to 22.55/100 000, 43.00/100 000, 46.27/100 000, 8.34/100 000, 13.82/100 000 in 2021. The new cases of esophageal cancer, stomach cancer, colorectal cancer, pancreatic cancer, and liver cancer all showed an increasing trend, with absolute changes of 54.61%, 50.15%, 315.64%, 213.78%, and 103.91%, respectively. (2) The mortality of 5 common malignant tumors of digestive system in the Chinese population from 1990 to 2021. The number of deaths of esophageal cancer, gastric cancer, colorectal cancer, pancreatic cancer and liver cancer in the Chinese population changed from 210 821, 374 066, 119 303, 38 883 and 94 937 in 1990 to 296 443, 445 013, 275 129, 119 602 and 172 068 in 2021. The crude death rates of the above cancer types changed from 17.92/100 000, 31.80/100 000, 10.14/100 000, 3.31/100 000, 8.07/100 000 in 1990 to 20.84/100 000, 31.28/100 000, 19.34/100 000, 8.41/100 000, 12.09/100 000 in 2021. Death cases of esophageal cancer, stomach cancer, colorectal cancer, pancreatic cancer, and liver cancer all showed an increa-sing trend, with absolute changes of 40.61%, 18.97%, 130.61%,207.59%, and 81.24%, respectively. (3) The change trend of age-standardized incidence rate of 5 common malignant tumors of digestive system in the Chinese population from 1990 to 2021. The change trends of age-standardized incidence rates of esophageal cancer, gastric cancer, colorectal cancer, pancreatic cancer, and liver cancer in the Chinese population were divided into 5, 5, 4, 5, and 5 periods, respectively, and the AAPCs of age-standardized incidence rates of the above cancer types were -1.60% (95% CI as -1.78% to -1.42%), -1.60% (95% CI as -1.78% to -1.43%), 1.66% (95% CI as 1.39% to 1.94%), 0.72% (95% CI as 0.36% to 1.08%), and -0.31% (95% CI as -0.39% to -0.23%). (4) The change trend of age-standardized mortality rate of 5 common malignant tumors of digestive system in the Chinese population from 1990 to 2021. The change trend of age-standardized mortality rates of esophageal cancer, gastric cancer, colorectal cancer, pancreatic cancer, and liver cancer in the Chinese population were divided into 5, 5, 4, 5, and 4 periods, respectively, and the AAPC of age-standardized mortality rates for each of the above mentioned cancer types were -1.96% (95% CI as -2.03% to -1.90%), -2.44% (95% CI as -2.50% to -2.38%), -0.49% (95% CI as -0.58% to -0.41%), 0.56% (95% CI as 0.48% to 0.63%), and -0.68% (95% CI as -0.89% to -0.52%). Conclusions:From 1990 to 2021, the disease burden of esophageal cancer, gastric cancer and liver cancer in the Chinese population show a downward trend. The standardized incidence of colorectal cancer shows an upward trend, and the standardized mortality rate shows a downward trend. The disease burden of pancreatic cancer shows an upward trend.
8.Analysis of the current situation and influencing factors of the treatment delay for lymphedema in breast cancer patients
Ruiqing LI ; Xing LI ; Yanyan WANG ; Ying LI ; Wei LIU ; Lulu ZHANG ; Jing LI ; Mengdi CAO ; Yaqing LIU
Chinese Journal of Practical Nursing 2025;41(34):2655-2663
Objective:To investigate the current status of treatment delay and analyze its influencing factors in patients with breast cancer-related lymphedema.Methods:Using convenience sampling, 218 patients with breast cancer-related lymphedema from The First Affiliated Hospital of Zhengzhou University between April 2024 and January 2025 were enrolled. The General Information Questionnaire, Lymphedema Self-Management Support Scale for Breast Cancer Survivors (LSMS-BCs), Brief Illness Perception Questionnaire for Breast Cancer-related Lymphedema (BIPQ-BCRL), Perceived Barriers to Health Care-Seeking Decision-Chinese (PBHSD-C), and Health Literacy Scale for Chronic Patients (HLSCP) were used to conduct a cross-sectional survey. Logistic regression identified predictors of treatment delay, with model fit assessed by the Hosmer-Lemeshow test. Discriminative ability was evaluated using receiver operating characteristic (ROC) curve analysis.Results:The study included 218 female BCRL patients, aged (58.31 ± 10.54) years. Among 218 patients, 76 experienced treatment delay, the incidence of treatment delay was 34.8% (76/218). Independent risk factors included junior high school education or below, no regular arm circumference measurement, low self-management support scores, low illness perception scores, high perceived barriers to healthcare-seeking scores, and low health literacy scores (Wald χ2 values were 7.75-15.15, all P<0.05). The Hosmer-Lemeshow test indicated good model fit ( χ2=6.21, P>0.05). The combined predictive model demonstrated significantly better discrimination than individual factors, the area under the curve of ROC was 0.846 ( P<0.01). Conclusions:The incidence of treatment delay is relatively high among breast cancer-related lymphedema patients. Nursing staff should pay special attention to patients with a junior high school education or below, no regular arm circumference measurement, low LSMS-BCs scores, low BIPQ-BCRL scores, high PBHSD-C scores and low HLSCP scores, implement timely interventions to reduce treatment delay in lymphedema patients.
9.Research progress on the compliance of lymphedema prevention behaviors in postoperative breast cancer patients
Mengdi CAO ; Yanyan WANG ; Xin CHEN ; Jing LI ; Liangyi YAO ; Xing LI
Chinese Journal of Modern Nursing 2025;31(5):561-566
This paper provides a review on the concept, current status, assessment tools, influencing factors, and intervention strategies regarding the compliance of lymphedema prevention behaviors in postoperative breast cancer patients. The aim is to improve the compliance of lymphedema prevention behaviors in these patients, reduce the incidence of lymphedema, and provide a reference for future clinical intervention studies in this field.
10.Trends and Decompostion of Disease Burden for Lung Cancer Worldwide and in China from 1990 to 2021
Tianyi LI ; Yuanjie ZHENG ; Yi TENG ; Qianru LI ; Tingting ZUO ; Nuopei TAN ; Jiachen WANG ; Siyi HE ; Mengdi CAO ; Changfa XIA ; Wanqing CHEN
China Cancer 2025;34(5):355-367
[Purpose]To analyze the trends of disease burden for lung cancer worldwide and in China from 1990 to 2021.[Methods]Data of the disease burden of lung cancer and population demographics in 1990 and 2021 stratified by sex and age groups for global,five SDI quintiles re-gions,and eight countries including China,Japan,Republic of Korea,United Kingdom,France,United States,Canada,and Australia were extracted from the Global Burden of Disease Study 2021(GBD 2021)database.The age-standardized mortality rate(ASMR)and age-standard-ized disability-adjusted life year rate(ASDR)of lung cancer attributable to 7 level-3 risk factors in China for 1990 and 2021 were also extracted.Counterfactual analysis was used to decompose changes in lung cancer deaths and DALY from 1990 to 2021 into four contributing factors:popu-lation size,population structure,age-standardized incidence or prevalence,and lung cancer case fatality or disease severity.The percentage changes in lung cancer deaths and DALY attributed to these four factors were calculated respectively.[Results]In 2021,there were 934 704 new cases and 814 364 deaths of lung cancer in China.From 1990 to 2021,the incidence,preva-lence,mortality,and DALY rates of lung cancer in China increased faster than those worldwide and in high-middle SDI regions,which was similar to Japan and Republic of Korea.In contrast,the mortality rates of lung cancer decreased in United States and United Kingdom;and the DALY rates of lung cancer decreased in United States,United Kingdom,Canada and Australia.From 1990 to 2021,the age-related lung cancer deaths and DALY in China increased by 193.91%and 146.20%,respectively.The primary contributor to the increase in lung cancer deaths was population aging(102.82%)among men and rising age-standardized incidence(119.00%)among women,while the primary contributor to the increase in DALY was rising age-standardized prevalence for both men(153.12%)and women(218.77%).In 2021,the top three risk factors contributing to lung cancer ASMR and ASDR in China were smoking,particulate matter pollution and occupational carcinogen exposure.Compared with 1990,the ASMR of lung cancer and its proportion at-tributable to particulate matter pollution and low dietary fruits were decreased,while the propor-tions in ASDR of lung cancer attributable to smoking and secondhand smoke increased.[Conclu-sion]Lung cancer is a major public health challenge in China.Compared with worldwide,high-middle SDI regions and certain developed countries,China has experienced faster growth in the incidence,prevalence,mortality and DALY of lung cancer,especially among women.To reduce disease burden,sustained efforts on lung cancer prevention and control are urgently required in China.

Result Analysis
Print
Save
E-mail